CMA1 and anaphylaxis: For the future outlooks concerning upcoming biomarkers and the acute management of anaphylaxis in pregnant women it is worth mentioning CCL2, a promising potential biomarker that seems less affected by the surgical setting, along with chymase and carboxypeptidase A3, and the possible role for combinations of mast cell tryptase and such novel biomarkers to augment sensitivity and specificity.